CDX-585

N/A

Report date: 2025/03/14 15:13:30

Base Information

Drug NameCDX-585
Drug Alias NameCDX-585BSI-585
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitorsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1Leukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesBiosion IncCelldex Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesBiosion IncCelldex Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A